다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc (EPRX) 뉴스

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:EPRX

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/02/25	21:48	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2025/02/25	21:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2025/02/25	21:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2025/02/18	21:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2025/02/18	21:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces CFO Succession	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2025/02/18	21:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces CFO Succession	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/20	22:57	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/20	21:00	PR Newswire (Canada)	Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/20	21:00	PR Newswire (US)	Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/15	07:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/15	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/15	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/14	07:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/14	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/14	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/13	07:56	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/13	07:56	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/09	01:49	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	07:17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	06:10	Edgar (US Regulatory)	Form SC 13D - General Statement of Acquisition of Beneficial Ownership	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/01	08:36	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/01	08:36	PR Newswire (US)	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/28	20:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/28	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/28	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/15	21:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/15	20:00	PR Newswire (Canada)	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/15	20:00	PR Newswire (US)	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis	NASDAQ:EPRX	Eupraxia Pharmaceuticals Inc

검색 관련기사 보기:NASDAQ:EPRX

1 2 3 다음 >>

iShares AI Innovation an...

Lyxor Asset Management

DAXsector All Industrial...

First Trust Indxx Innova...

SPDR S&P Oil and Gas Equ...

DAXsector Insurance Kurs

Saratoga Investment

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관